Ramani Ananthakrishnan, Udeani George, Evans John, Jandourek Alena, Cole Phillip, Smith Alexander, David Friedland H
J Chemother. 2014 Aug;26(4):229-34. doi: 10.1179/1973947814Y.0000000184. Epub 2014 Mar 20.
The Clinical Assessment Program and Teflaro(®) Utilization Registry (CAPTURE) is a multicenter cohort study designed to collect information on the contemporary use of ceftaroline fosamil in the US. Data collected from 398 evaluable patients with community-acquired bacterial pneumonia (CABP) (mean age 64 years) during the first 18 months of the study are presented. Most patients had co-morbidities (76%; primarily structural lung disease), and ≧2 signs and symptoms of CABP (76%). Overall clinical success was 79% which varied little with ceftaroline fosamil usage (monotherapy vs concurrent therapy; first-line vs second-line therapy). Most patients were discharged home (60%) or to another healthcare facility (35%). These data suggest that ceftaroline, in contemporary clinical use, is an effective antibiotic for the treatment of patients with CABP, including those with significant co-morbidities or who required a change of their prior antibiotic therapy.
临床评估项目及替加环素（Teflaro®）使用登记研究（CAPTURE）是一项多中心队列研究，旨在收集美国当代使用头孢洛林酯的相关信息。本文呈现了研究前18个月从398例可评估的社区获得性细菌性肺炎（CABP）患者（平均年龄64岁）收集的数据。大多数患者有合并症（76%；主要是结构性肺病），且有≥2种CABP的体征和症状（76%）。总体临床成功率为79%，其在使用头孢洛林酯（单药治疗与联合治疗；一线治疗与二线治疗）方面变化不大。大多数患者出院回家（60%）或转至另一医疗机构（35%）。这些数据表明，在当代临床应用中，头孢洛林是治疗CABP患者的一种有效抗生素，包括那些有显著合并症或需要更换先前抗生素治疗的患者。
